Company Overview: InspireMD

Industry News

8 Jul

InspireMD Announces Closing of Public Offering of Approximately $14.6 Million

BOSTON, MA–(Marketwired – Jul 7, 2016) –  InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the closing of a “best efforts” public offering of 442,424 shares of Series B Convertible Preferred Stock and accompanying warrants...

Read more

14 Jun

InspireMD Announces Amendment to Loan & Security Agreement With Hercules Capital

Principal Payments Deferred, Assisting Cash Management Programs BOSTON, MA–(Marketwired – Jun 14, 2016) –  InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that it has completed a restructuring of its existing debt. The Company restructured its...

Read more

7 Jun

InspireMD Names Dr. James Barry as President and CEO

Medical Device Veteran Brings Broad Industry Experience in Pioneering Technologies BOSTON, MA–(Marketwired – Jun 7, 2016) – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the appointment of James Barry, Ph.D. as President and CEO effective...

Read more

17 May

InspireMD’s CGuard(TM) Highlighted at the Late-Breaking Clinical Trial Session at the EuroPCR 2016 Conference

BOSTON, MA–(Marketwired – May 17, 2016) –  InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that CGuard™ EPS reported positive results in PARADIGM-101, an investigator led clinical evaluation of the system for routine use in 101...

Read more

10 May

InspireMD Reports Financial Results for the First Quarter Ended March 31, 2016

BOSTON, MA–(Marketwired – May 10, 2016) – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced its financial and operating results for the first quarter ended March 31, 2016. During the first quarter, InspireMD announced initiatives to...

Read more

5 May

InspireMD Announces Late-Breaking Trial Presentation on CGuard(TM) Embolic Prevention System at EuroPCR 2016 Conference

BOSTON, MA–(Marketwired – May 5, 2016) – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that CGuard™ EPS will be featured at the Late-Breaking Trial presentation at the upcoming EuroPCR conference from May 17-20, 2016 in...

Read more

1 Apr

UPDATE: InspireMD Receives Audit Opinion With Going Concern Explanation

BOSTON, MA–(Marketwired – Mar 31, 2016) –  InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2015, which was...

Read more

28 Mar

InspireMD Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015

BOSTON, MA–(Marketwired – Mar 28, 2016) –  InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced its financial and operating results for the fourth quarter and year ended December 31, 2015. In 2015, InspireMD advanced its strategic...

Read more

Page 1 of 512345

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address